Industry News
Potential Drug Targets In Common Childhood Brain Tumor Identified By Gene Sequencing Project
Jun 22, 2012
Researchers studying the genetic roots of the most common malignant childhood brain tumor have discovered missteps in three of the four subtypes of the cancer that involve genes already targeted for drug development. The most significant gene alterations are linked to subtypes of medulloblastoma that currently have the best and worst prognosis... Read More
New Genetic Alterations Discovered Through US-Mexico Sequence-Analysis Collaboration
Jun 22, 2012
Breast cancer is not a single disease, but a collection of diseases with dozens of different mutations that crop up with varying frequency across different breast cancer subtypes. Deeper exploration of the genetic changes that drive breast cancer is revealing new complexity in the leading cause of cancer death in women worldwide... Read More
New Blood Thinning Drugs Under The Microscope
Jun 22, 2012
Scientists have examined strategies to reverse the effects of new blood thinning drugs, to stop dangerous bleeding in case of an accident or emergency surgery. Many people in the UK take blood thinning drugs to reduce their risk of stroke. In an emergency situation, where a patient is likely to bleed heavily, doctors need to reverse the blood thinning effects and encourage the blood to clot... Read More
New Blood Thinning Drugs Under The Microscope
Jun 22, 2012
Scientists have examined strategies to reverse the effects of new blood thinning drugs, to stop dangerous bleeding in case of an accident or emergency surgery. Many people in the UK take blood thinning drugs to reduce their risk of stroke. In an emergency situation, where a patient is likely to bleed heavily, doctors need to reverse the blood thinning effects and encourage the blood to clot... Read More
Revlimid (lenalidomide) Extension Of Indication Submission Withdrawn, Europe
Jun 21, 2012
The European Medicines Agency has been informed by Celgene Europe Limited that it has withdrawn its submission for approval for Revlimid (lenalidomide) - an application for an extension of the therapeutic indication in newly diagnosed multiple myeloma (blood cancer) patients, as well as new pack sizes had been sought... Read More
Revlimid (lenalidomide) Extension Of Indication Submission Withdrawn, Europe
Jun 21, 2012
The European Medicines Agency has been informed by Celgene Europe Limited that it has withdrawn its submission for approval for Revlimid (lenalidomide) - an application for an extension of the therapeutic indication in newly diagnosed multiple myeloma (blood cancer) patients, as well as new pack sizes had been sought... Read More
Job Factors Linked To 8,000 Cancer Deaths A Year In Britain
Jun 21, 2012
A new study that examines how the jobs of British workers affects their risk of cancer, concludes that over 8,000 cancer deaths a year in Britain, that is 5% of all cancer deaths, are linked to occupations, especially those involving shift work or exposure to carcinogens like asbestos and diesel engine fumes... Read More
UF Targets Known Barriers To Preventing Cervical Cancer
Jun 21, 2012
The human papillomavirus vaccine can protect against cervical cancer, yet only one-fifth of adolescent girls on Medicaid in Florida receive the vaccine, even though it's free for them, University of Florida researchers say... Read More
UF Targets Known Barriers To Preventing Cervical Cancer
Jun 21, 2012
The human papillomavirus vaccine can protect against cervical cancer, yet only one-fifth of adolescent girls on Medicaid in Florida receive the vaccine, even though it's free for them, University of Florida researchers say... Read More
Tobacco Use Overlooked By Most Cancer Trials, Study Finds
Jun 21, 2012
Tobacco use can negatively impact cancer treatment, but few studies incorporate assessment or cessation support While tobacco use can significantly hamper cancer treatment, few cancer researchers are incorporating tobacco assessment into their clinical studies... Read More
Previous Page Next Page